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ABSTRACT
Staging systems for multiple myeloma (MM) include the Southwest Oncology Group (SWOG) staging system,
the International Staging System (ISS), and the Durie-Salmon (DS) staging system. We evaluated whether
staging at the time of diagnosis could predict survival in MM patients undergoing autologous peripheral blood
stem cell transplantation (APBSCT) as first-line treatment. Between November 1996 and June 2005, 152 MM
patients were treated with induction VAD (vincristine, adriamycin, dexamethasone) chemotherapy, followed by
APBSCT at 6 institutions in Korea. Median follow-up times were 22.6 months (range, 5.4-101.9 months) from
the day of diagnosis and 14.1 months (range, 0.4-96.1 months) from the day of APBSCT. Progression-free
survival (PFS) from the day of diagnosis was predicted by the SWOG staging system (P  .0129) and ISS (P 
.0299), but not by the DS staging system at diagnosis (P  .1074). In addition, overall survival (OS) from the
day of diagnosis could be predicted by the SWOG staging system (P  .0207) and ISS (P  .0105), but not by
the DS staging system (P  .2542). PFS from day of APBSCT was not predicted by the DS staging system (P 
.5731), SWOG staging system (P  .2817), or ISS (P  .1167). OS from day of APBSCT could be predicted by
the SWOG staging system (P  .0392) and ISS (P  .0198), but not by the DS staging system (P  .5426). Our
findings indicate that PFS and OS in association with APBSCT can be predicted by stages assessed by the
SWOG and ISS systems, but not by the DS system. Moreover, staging by the SWOG and ISS systems at the
time of diagnosis was better correlated with survival than was staging at the time of APBSCT.
© 2006 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Despite its many complex criteria, the Durie-
almon (DS) staging system has been the standard
taging tool for patients with multiple myeloma
MM). Recently, the Southwest Oncology Group fSWOG) published a new, simpliﬁed staging system,
ocusing on 2 commonmeasures with prognostic impor-
ance in MM: serum beta2-microblobulin (beta2M) and
erum albumin [1]. The SWOG staging system was
ound to correlate well with survival and DS staging.
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H. Kim et al.838ore recently, the International Staging System (ISS)
as introduced. The ISS is similar to the SWOG
taging system in that serum beta2M and albumin are
he main determinants of staging; however, the ISS
as 3 stages rather than the 4 stages of the SWOG
taging system [2]. The DS staging system was devel-
ped based on the clinical manifestations of a small
umber of patients, whereas both the SWOG staging
ystem and the ISS are based on prognostic studies of
arger populations.
Autologous peripheral blood stem cell transplan-
ation (APBSCT) has become a standard therapeutic
odality for MM to prolong disease-free interval
3,4]. The existence of 3 major staging systems for
M raises the question of which staging system has
he most prognostic value for patients undergoing
PBSCT. In addition, the prognosis of patients with
M can depend not only on staging at diagnosis, but
lso on stage just before APBSCT and the response to
nitial therapy. Therefore, it is important to determine
hether staging just before APBSCT is more predictive
f prognosis than staging at diagnosis. Consequently, we
ompared these 3 staging systems in patients undergoing
PBSCT and also evaluated the best time point at which
o estimate prognosis.
ETHODS
ata Collection
We collected basic information and staging scores
f patients with MM who underwent APBSCT at 6
nstitutions in Korea between November 1996 and
une 2005. All patient data were obtained retrospec-
ively from case report form questionnaires. Each
uestionnaire contained information about patient
ge, sex, date of diagnosis, immunoglobulin subtype,
taging scores (DS, SWOG, and ISS) at the time of
iagnosis and at the time of APBSCT, conditioning
egimen, disease status at APBSCT, date of APBSCT,
esponse to APBSCT, date of response to APBSCT,
ate of last follow-up, survival status, and date of pro-
ression. For patients who underwent tandemAPBSCT,
e evaluated the data for the ﬁrst APBSCT.
Patients excluded from the initial database in-
luded those who did not undergo APBSCT, those
ho did not undergo APBSCT as ﬁrst-line therapy,
nd those for whom we had no data on serum albumin
r serum beta2M concentration at diagnosis and/or
ime of APBSCT.
isease
MMwas diagnosed by the presence of monoclonal
ammopathy, the presence of 10% plasma cells
mong bone marrow nuclear cells, and impairment of
related organ or tissue, including an osteolytic bone
esion, anemia, or azotemia. Patients were initiallylassiﬁed by DS stage and later reclassiﬁed by
WOG/ISS.
After 3 or more cycles of VAD (vincristine, adria-
ycin, dexamethasone) chemotherapy, patients un-
erwent APBSCT regardless of their response to
AD. Each patient gave written informed consent to
ndergo APBSCT.
PBSCT
Peripheral blood hematopoietic stem cells were
obilized with cyclophosphamide and hematopoietic
rowth factor (HPGF), with the latter consisting of
ither granulocyte-colony stimulating factor or gran-
locyte-monocyte–colony stimulating factor. Infusion
f at least 3  106 CD34 cells/kg among the col-
ected mononuclear cell (MNC) was recommended.
either CD34-positive selection nor purging was ap-
lied.
The conditioning regimen was melphalan 100
g/m2 for 2 days. HPGF support was given until
ematologic engraftment occurred, with hematologic
ngraftment deﬁned as the ﬁrst day of absolute neu-
rophil count (ANC) 500 cells/L for 3 consecutive
ays. After disease progression, salvage therapy was
one at the discretion of the attending physician.
tage Classification
Until 2003, DS stage was used to classify MM
atients at the time of diagnosis. There are 3 DS
tages (I, II, and III), each of which is divided into
able 1. Basic Characteristics of MM Patients
Characteristic No. of Patients (%)
Total 152 (100)
Sex
Male 82 (54.2)
Female 70 (45.8)
Age >50 years 96 (63.2)
Immunoglobulin type
IgG/kappa 51 (33.6)
IgG/lambda 23 (15.1)
IgA/kappa 18 (11.8)
IgA/lambda 13 (8.6)
IgD/lambda 11 (7.2)
Free kappa 13 (8.6)
Free lambda 15 (9.9)
Others 5 (3.3)
Disease status at APBSCT
First CR 36 (23.7)
Initial PR 100 (65.8)
Primary refractory 16 (10.5)
Responses to APBSCT
Continued CR 36 (23.7)
Induced CR 50 (32.9)
Induced or continued PR 55 (36.2)
Stable disease 3 (2)
Progressive disease 2 (1.3)
Not evaluated 6 (3.9)
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New Staging Systems after APBSCT in Multiple Myeloma 839ubclasses A and B according to serum creatinine
evel. Patients were sorted into DS stage I, II, or II
egardless of subclass to simplify the analysis. The
atients were reclassiﬁed by SWOG stage according
o their serum albumin and beta2M levels at the time
f diagnosis and at the time of APBSCT, with SWOG
tage I deﬁned as beta2M 2.5 mg/L; stage II, as
.5  beta2M 5.5 mg/L; stage III, as beta2M 5.5
g/L and albumin  3 g/dL; and stage IV, as beta2M
5.5 mg/L and albumin 3 g/dL. The patients were
lso reclassiﬁed by ISS stage, with ISS stage I deﬁned
s beta2M 3.5 mg/L and albumin 3.5 g/dL; stage
I, as all patients not assorted into stage I or III; and
tage III, as beta2M 5.5 mg/L. Stage at diagnosis
as compared with stage just before APBSCT and
ategorized as “improved,” “no change,” or “aggra-
ated.”
esponse Evaluation
Protein electrophoresis and immunoﬁxation elec-
rophoresis in serum and/or urine was used to evaluate
esponse and progression. Simple X-ray, computed
omography, or magnetic resonance imaging was used
or imaging evaluation. Positron emission tomogra-
hy was not used to determine progression. Disease
tatus at APBSCT was categorized as ﬁrst complete
emission (CR), initial partial remission (PR), or pri-
ary refractory. Response to therapy was based on
riteria in patients with MM treated with high-dose
herapy and hematopoietic stem cell transplantation
Blade criteria) [5]. Response to APBSCT was classi-
ed as continued CR, induced CR, induced or con-
inued PR, stable disease, progressive disease, or not
valuated.
able 2. Staging of MM Patients According to the DS Staging System
Stage at Diagnosis I
8 (5.3%)
I 9 (5.9%)
II 26 (17.1%)
otal 43 (28.3%)
able 3. Staging of MM Patients According to the SWOG Staging Sy
Stage at Diagnosis I II
25 (16.4%) 11 (7.2%)
I 32 (21.1%) 35 (23.0%)
II 4 (2.6%) 8 (5.3%)
V 3 (2.0%) 11 (7.2%)
otal 64 (42.1%) 65 (42.8%)urvival Data
Progression-free survival (PFS) was calculated as
he time interval between the starting point and the
ate of ﬁrst progression after APBSCT. If a patient
id not progress, then the end point for PFS was the
ate of last follow-up, and the patient was censored.
verall survival (OS) was calculated as the time inter-
al between the starting point and the date of last
ollow-up. Patients alive at last follow-up were cen-
ored from analysis of OS. Any death was deﬁned as an
vent regardless of cause. On progression or relapse,
he second-line therapy was instituted at the discre-
ion of the attending physician.
tatistical Analysis
The 2 test was used to compare nonnumerical
ariables among groups. The start dates of all time
ariables were day of diagnosis and day of APBSCT.
ll 4 time intervals were used for the 3 staging sys-
ems: OS from day of diagnosis, OS from day of
PBSCT, PFS from day of diagnosis, and PFS from
ay of APBSCT. Stage at time of diagnosis was eval-
ated by OS or PFS from day of diagnosis, whereas
tage at time of APBSCT was evaluated by OS or PFS
rom day of APBSCT. The Kaplan-Meier method was
sed to assess OS and PFS, and 2-tailed log-rank tests
ere used to compare OS and PFS curves. Quantita-
ive variables are reported as medians (range), and
ualitative variables are reported as number of pa-
ients (percentage) unless speciﬁed otherwise. A
value.05 was considered signiﬁcant. Hazard ratios
HRs) were calculated using the Cox regression
odel.
Stage at APBSCT
III Total
%) 3 (2.0%) 14 (9.2%)
) 1 (.7%) 11 (7.2%)
.5%) 85 (55.9%) 127 (83.6%)
.2%) 89 (58.6%) 152 (100.0%)
Stage at APBSCT
III IV Total
1 (.7%) 0 (.0%) 37 (24.3%)
4 (2.6%) 2 (1.3%) 73 (48.0%)
13 (8.6%) 0 (.0%) 25 (16.4%)
2 (1.3%) 1 (.7%) 17 (11.2%)II
3 (2.0
1 (.7%
16 (10stem20 (13.2%) 3 (2.0%) 152 (100.0%)
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H. Kim et al.840ESULTS
atient Characteristics
Data were collected from initial questionnaires on
11 patients who underwent APBSCT, with the data
ocked as of November 12, 2005. Data on 12 patients
ere ineligible because of a second APBSCT. We also
xcluded 7 patients who underwent APBSCT after
elapse and 1 patient in whom poor mobilization dis-
urbed completion of APBSCT. SWOG/ISS staging
as not available for 15 patients at the time of diag-
osis, for 29 patients at the time of APBSCT, and at
ither time point for 4 patients. Thus, data on 152
atients were deemed eligible for analysis.
Of these 152 patients, 82 (53.9%) were men and
0 (46.1%) were women. Their median age was 54
ears (range, 20-69 years). The most common immu-
oglobulin type was IgG/ (n  51; 33.6%). The date
f APBSCT was between November 23, 1996 and
une 15, 2005. More than half of the patients (56.6%)
ere either continued CR or induced PR as a response
o APBSCT. Patient characteristics are summarized in
able 1.
tages
At the time of diagnosis, most patients were in an
dvanced stage according to the DS staging system
83.6% in stage III; Table 2) in contrast to SWOG
11.2% in stage IV; Table 3) and ISS (27.6% in stage III;
able 4). Before APBSCT, the number of patients in an
dvanced stage was reduced not only in SWOG (2% in
tage IV) and ISS (13.8% in stage III), but also in DS
83.6% in stage III). According to the DS staging
ystem, many patients showed improvement after
PBSCT compared with time of diagnosis (P .001);
1 (33.5%) patients improved, 94 (61.9%) remained
he same, and 7 (4.7%) worsened after APBSCT. The
ame tendency was observed using the SWOG staging
ystem (P .001) and ISS (P .001), although the
roportion showing improvement after APBSCT was
arger for SWOG and ISS than for the DS staging
ystem. According to the SWOG staging system, 60
39.5%) patients improved, 74 (48.7%) remained the
ame, and 18 (11.8%) worsened; whereas according to
he ISS, 75 (49.3%) patients improved, 66 (43.4%) re-
able 4. Staging of MM Patients According to the ISS
Stage at Diagnosis I
35 (23.0%)
I 47 (30.9%)
II 12 (7.9%)
otal 94 (61.8%)ained the same, and 11 (7.2%) worsened. Nurvival from Day of Diagnosis
The median follow-up from day of diagnosis was
2.6 months (range, 5.4-101.9 months), whereas the
edian follow-up from day of APBSCT was 14.1
onths (range, 0.4-96.1 months). None of the 152 pa-
ients was lost to follow-up. Progression after ABPSCT
as observed in 81 patients (53.3%). As shown in Table
, PFS from day of diagnosis was not predicted by the
S staging system at diagnosis (P  .1074, HR 
.387; Fig 1A), but was predicted by both the SWOG
taging system (P  .0129, HR  1.335; Fig 1B) and
SS (P  .0299, HR  1.379; Fig 1B). Differences in
FS were signiﬁcant only between stages I and IV
ccording to the SWOG staging system and between
tages I and III according to the ISS. Staging at
PBSCT was not predictive of PFS from day of diag-
osis according to the SWOG system (P  .2994,
R  1.152), ISS (P  .3120, HR  1.130), or DS
taging system (P  .116, HR  1.282).
As of November 2005, 38 patients (25%) had died,
5 from disease progression, 9 from infection, 1 from
Stage at APBSCT
III Total
%) 3 (2.0%) 42 (27.6%)
.2%) 4 (2.6%) 68 (44.7%)
.5%) 14 (9.2%) 42 (27.6%)
.3%) 21 (13.8%) 152 (100.0%)
able 5. PFS and OS from Day of Diagnosis When Stages were
valuated at the Time of Diagnosis
Survival System Stage n (Event)
Median,
Months P
FS DS 1 14 (7) 31.32 .1074
2 11 (4) NR
3 127 (70) 24.08
SWOG 1 37 (18) 33.62 .0129
2 73 (38) 24.67
3 25 (14) 38.22
4 17 (11) 19.80
ISS 1 42 (17) 32.83 .0299
2 68 (39) 23.52
3 42 (25) 22.53
S DS 1 14 (4) 44.87 .5426
2 11 (2) NR
3 127 (32) 66.58
SWOG 1 37 (5) NR .0207
2 73 (16) 68.59
3 25 (10) 37.14
4 17 (7) 45.53
ISS 1 42 (5) NR .0105
2 68 (16) 68.59
3 42 (17) 45.53II
4 (2.6
17 (11
16 (10R, not reached.
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igure 1. PFS curves of 152 MM patients after APBSCT (Kaplan-Meier curves). A–C, PFS from day of diagnosis according to DS staging
A), SWOG staging (B), and the ISS (C) at time of diagnosis. D–F, PFS from day of APBSCT according to DS staging (D), SWOG staging
E), and the ISS (F) at time of APBSCT. Stage I is represented by the thick solid line; stage II, by the dotted line; stage III, by the solid line;
nd stage IV, by the thick dotted line.
841
b
c
f
s
1
I
c
d
1
a
2
U
o
w
S
a
s
r
.
F
a
t
w
.
F
b
.
(
s
O
H
(
d
V
i
s
r
d
f
S
s
d
w
S
I
s
D
w
i
t
t
h
m
[
o
w
s
o
m
t
w
b
p
s
s
I
n
s
t
c
w
t
i
r
t
j
w
p
a
c
A
o
s
t
t
A
t
l
b
s
t
a
S
a
s
p
t
c
v
t
d
m
H. Kim et al.842one marrow aplasia, 1 from suicide, and 2 from other
auses. Eighty-one patients (53.3%) had relapsed. OS
rom day of diagnosis was not predicted by the DS
taging system, either at diagnosis (P  .2542, HR 
.144) or at APBSCT (P .5426, HR 1.391) (Fig 2A).
n contrast, both the SWOG staging system and ISS
ould predict OS from day of diagnosis, either at
iagnosis (P  .0207 and .0105, HR  1.593 and
.642, respectively; Fig 2B) or at APBSCT (P  .0198
nd .0054; HR  1.585 and 1.734, respectively; Fig
C). OS from day of diagnosis is presented in Table 5.
sing these staging systems, only stage I differed from
ther stages, however. This tendency was ampliﬁed
hen patients were restaged at APBSCT.
urvival from Day of APBSCT
PFS from day of APBSCT, either at diagnosis or
t APBSCT, was not predicted by the DS staging
ystem (P  .1644 and .5731; HR  1.219 and 1.147,
espectively; Fig 1D), the SWOG staging system (P
2660 and .2817; HR  1.231 and 1.198, respectively;
ig 1E), or the ISS (P .2233 and .1167; HR 1.304
nd 1.734, respectively; Fig 1F). In addition, OS from
he day of APBSCT either at diagnosis or at APBSCT
as not predicted by the DS staging system (P 
2542 and .5426; HR  1.059 and 1.250, respectively;
ig 2D). In contrast, OS from day of APBSCT could
e predicted by the ISS from the day of diagnosis (P
0207, HR  1.841) and from the day of APBSCT
P .0198, HR 1.629; Fig 2F). The SWOG staging
ystem was intermediate, in that it could not predict
S from the day of ABPSCT at diagnosis (P  .0553,
R  1.506) but could do so at the day of APBSCT
P  .0392, HR  1.585; Fig 2E). Survival from the
ay of APBSCT is summarized in Table 6.
We also determined whether stage shift after
AD chemotherapy could alter survival. Compar-
ng patients showing improved stage with patients
howing no change or aggravation for PFS and OS
evealed no between-group differences in PFS from the
ay of diagnosis, PFS from the day of APBSCT, OS
rom the day of diagnosis, or OS from the day of APB-
CT, except that the improvement in SWOG staging
ystem was predictive of longer PFS from the day of
iagnosis (P .0332). Responses to VAD chemotherapy
ere not associated with the stage shift in DS stage and
WOG (P  .939 and .455, respectively), but improved
SS after VAD exhibited a tendency toward good re-
ponse (P  .094).
ISCUSSION
In general practice, almost all patients with MM
ho are under age 65 years undergo APBSCT after
nitial chemotherapy, (eg, VAD), thus emphasizing
he prognostic factors for ASCT. High serum concen- crations of beta2M, C-reactive protein, or lactate de-
ydrogenase and low serum concentrations of albu-
in have all been associated with poorer outcome
6,7]. The presence of chromosome 13 deletions and
ther chromosomal abnormalities is also associated
ith worse survival [8-12]. Both the SWOG staging
ystem and the ISS were based on prognostic analysis
f large populations and use serum beta2M and albu-
in concentrations as prognostic markers. Because
heir detailed applications are somewhat different, we
ished to determine which of these staging systems is
etter for patients undergoing APBSCT.
We found that PFS from the day of diagnosis was
redicted by SWOG staging and ISS, but not by DS
taging, although longer PFS was observed only for
tage I according to the SWOG staging system and
SS. In contrast, PFS from the day of APBSCT was
ot predicted by any of the 3 staging systems. The DS
taging system also was not prognostic of OS, either at
ime of diagnosis or at time of APBSCT. The OS
urves of SWOG stages II and III crossed over,
hereas the OS curves of the different ISS stages at
he time of diagnosis were distinct. These ﬁndings
ndicate that the ISS, which was simple and well cor-
elated with both PFS and OS, was more prognostic
han the DS and SWOG staging systems.
Another concern was the signiﬁcance of staging
ust before APBSCT. DS staging at time of diagnosis
as not correlated with either PFS or OS. In contrast,
atients in SWOG or ISS stage I exhibited longer OS
t both time of diagnosis and time of APBSCT. OS
urves of SWOG and ISS stages II and III at time of
PBSCT could not be distinguished from one an-
ther, however. Factors associated with signiﬁcantly
horter OS after APBSCT were lack of CR after
ransplantation, ISS stage III, and age 60 years at
ransplantation [13]. The status of disease before
SCT did not signiﬁcantly affect PFS and OS after
ransplantation. Patients in SWOG or ISS stage I had
onger OS when reevaluated at the time of APBSCT,
ut stage evaluation at the time of APBSCT was not
uperior to, and did not provide more information
han, stage at diagnosis. Patients in SWOG stages II
nd III had similar OS curves, indicating that the
WOG staging system was less correlated with PFS
nd OS compared with the ISS.
According to all 3 staging systems, many patients
howed improvement at the time of APBSCT com-
ared with the time of diagnosis. Comparing the pa-
ients with improved stage with the patients with no
hange or aggravation in terms of PFS and OS re-
ealed that only improvements in SWOG staging af-
er VAD chemotherapy had a longer PFS from day of
iagnosis. In contrast, improved stage after VAD che-
otherapy according to the DS staging system and ISS
ould not be correlated with longer PFS or OS, suggest-
F
t
S
tigure 2. Overall survival (OS) curves of 152 MM patients after APBSCT (Kaplan-Meier curves). A–C, OS from day of diagnosis according
o DS staging (A), SWOG staging (B), and the ISS (C) at time of diagnosis. D–F. OS from day of APBSCT according to DS staging (D),
WOG staging (E), and the ISS (F) at time of APBSCT. Stage I is denoted by the thick solid line; stage II, by the dotted line; stage III, by
he solid line; and stage IV, by the thick dotted line.
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H. Kim et al.844ng that stage reevaluation just before APBSCT has no
igniﬁcance for PFS and OS.
Although OS is the ultimate end point for any
taging system, many factors after APBSCT interfere
ith interpretation of staging. One limitation of our
tudy was our inability to evaluate other prognostic
actors, including chromosome aberrations, and labo-
atory ﬁndings, including S-phase plasma cells, mi-
rovessel density, lactic dehydrogenase and C-reactive
rotein levels, salvage therapy after progression, and
ene expression proﬁles [14-18]. Moreover, we could
ot perform multivariate analysis for PFS and OS,
ecause our data were limited mainly to stage. There-
ore, the prognostic signiﬁcance in this study should
e conﬁned to staging systems. Another pitfall is that
edian follow-up after transplantation is short; the
ctual prognosis after APBSCT can change after
onger follow-up. Despite this drawback, however, it
ill be possible to suggest which time point (at the
ime of diagnosis vs at the time of APBSCT) is more
rognostic based on our results.
Although our ﬁndings may be insufﬁcient to val-
date various staging systems for MM patients under-
oing APBSCT, our study focused only on the prog-
ostic signiﬁcance of these staging systems for OS and
FS. Our results indicate that the DS staging system
s not suitable for MM patients undergoing APBSCT,
hereas both the SWOG and ISS staging systems
ave powerful prognostic value for OS and PFS. Our
ndings also indicate that the day of diagnosis is op-
imal for staging evaluation when APBSCT is being
able 6. PFS and OS from the Day of APBSCT when Stages were
valuated at the Time of APBSCT
Survival System Stage n (Event)
Median,
Months P
FS DS 1 43 (18) 26.45 .5731
2 20 (13) 35.39
3 89 (50) 28.31
SWOG 1 64 (33) 31.22 .2817
2 65 (38) 24.08
3 20 (8) 32.01
4 3 (2) 39.84
ISS 1 94 (49) 30.20 .1167
2 37 (22) 21.81
3 21 (10) 35.39
S DS 1 43 (7) NR .3629
2 20 (5) 57.24
3 89 (26) 39.84
SWOG 1 64 (9) NR .0392
2 65 (22) 40.03
3 20 (5) 32.01
4 3 (2) 39.84
ISS 1 94 (17) NR .0146
2 37 (14) 31.61
3 21 (7) 39.84
R, not reached.onsidered as an upfront therapy.EFERENCES
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